Cefuroxime versus ampicillin plus chloramphenicol in childhood bacterial meningitis: a multicenter randomized controlled trial. 1986

W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison

In a multicenter randomized trial, 107 children with bacterial meningitis were initially given either cefuroxime or ampicillin plus chloramphenicol. Patients were alternately assigned to 7- or 10-day courses of the designated antimicrobial regimen. CSF isolates included Haemophilus influenzae type b (89, of which 25% were beta-lactamase positive), Streptococcus pneumoniae, and Neisseria meningitidis. Although mean CSF bactericidal titers against Haemophilus isolates were 1:6 in each treatment group, H. influenzae was cultured from CSF in four of 39 patients receiving cefuroxime, 24 to 48 hours after initiation of therapy, compared with none of 40 patients given ampicillin plus chloramphenicol (P = 0.11). Clinical cure rates were similar (95%); one death occurred in each group. One child given cefuroxime had persistent meningitis after 5 days of therapy, and mastoiditis with secondary bacteremia developed in one on day 10. Three patients had relapse or reinfection. One patient who received cefuroxime for 10 days had a relapse of epiglottitis 17 days later, and of the patients given ampicillin plus chloramphenicol, one had a relapse of meningitis 1 week after 7 days of therapy, and bacteremia developed in one 42 days after completion of 10 days of therapy. No increase in either in-hospital complications or relapses occurred with a 7-day treatment course. Proof of the equivalence of the antibiotic regimens and the efficacy of 7-day courses of treatment, as well as the consequences of delayed CSF sterilization, will require additional investigation.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008583 Meningitis, Haemophilus Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults. Haemophilus influenzae Meningitis Type B,Hemophilus influenzae Meningitis Type B,Meningitis, Haemophilus influenzae Type F,Meningitis, Haemophilus parainfluenzae,Meningitis, Hemophilus,Meningitis, Hemophilus influenzae Type F,Meningitis, Hemophilus influenzae, Type B,Meninigitis, HiB,Type B Haemophilus influenzae Meningitis,Type B Hemophilus influenzae Meningitis,Haemophilus Meningitides,Haemophilus Meningitis,Haemophilus parainfluenzae Meningitides,Haemophilus parainfluenzae Meningitis,Hemophilus Meningitides,Hemophilus Meningitis,HiB Meninigitis,Meningitides, Haemophilus,Meningitides, Haemophilus parainfluenzae,Meningitides, Hemophilus
D008585 Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8) Meningitis, Neisseria,Neisseria Meningitis,Meningitis, Meningococcal, Serogroup A,Meningitis, Meningococcal, Serogroup B,Meningitis, Meningococcal, Serogroup C,Meningitis, Meningococcal, Serogroup W-135,Meningitis, Meningococcal, Serogroup W135,Meningitis, Meningococcal, Serogroup Y,Meningitis, Meningococcic,Meningococcal Meningitis, Serogroup A,Meningococcal Meningitis, Serogroup B,Meningococcal Meningitis, Serogroup C,Meningococcal Meningitis, Serogroup W-135,Meningococcal Meningitis, Serogroup W135,Meningococcal Meningitis, Serogroup Y,Serogroup A Meningococcal Meningitis,Serogroup B Meningococcal Meningitis,Serogroup C Meningococcal Meningitis,Serogroup W-135, Meningococcal Meningitis,Serogroup W135, Meningococcal Meningitis,Serogroup Y, Meningococcal Meningitis,Meningococcal Meningitis,Meningococcal Meningitis, Serogroup W 135,Neisseria Meningitides,Serogroup W 135, Meningococcal Meningitis
D008586 Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111) Meningitis, Streptococcus pneumoniae,Experimental Pneumococcal Meningitis,Meningitis, Pneumococcal, Experimental,Meningitis, Pneumococcal, Penicillin-Resistant,Meningitis, Pneumococcal, Recurrent,Experimental Pneumococcal Meningitides,Meningitides, Streptococcus pneumoniae,Meningitis, Experimental Pneumococcal,Pneumococcal Meningitides,Pneumococcal Meningitides, Experimental,Pneumococcal Meningitis,Pneumococcal Meningitis, Experimental,Streptococcus pneumoniae Meningitides,Streptococcus pneumoniae Meningitis
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
January 1988, Scandinavian journal of infectious diseases,
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
February 1982, Lancet (London, England),
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
September 1985, Lancet (London, England),
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
October 1991, Lancet (London, England),
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
September 1984, The Journal of antimicrobial chemotherapy,
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
January 1993, The Turkish journal of pediatrics,
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
June 1983, Lancet (London, England),
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
October 2002, Current infectious disease reports,
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
March 1990, The Journal of pediatrics,
W A Marks, and H R Stutman, and M I Marks, and J S Abramson, and E M Ayoub, and S A Chartrand, and F E Cox, and W A Geffen, and C J Harrison, and D Harrison
September 1985, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!